Roger Maansson

958 total citations
20 papers, 425 citations indexed

About

Roger Maansson is a scholar working on Epidemiology, Microbiology and Surgery. According to data from OpenAlex, Roger Maansson has authored 20 papers receiving a total of 425 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Epidemiology, 14 papers in Microbiology and 1 paper in Surgery. Recurrent topics in Roger Maansson's work include Bacterial Infections and Vaccines (13 papers), Pneumonia and Respiratory Infections (12 papers) and Virology and Viral Diseases (6 papers). Roger Maansson is often cited by papers focused on Bacterial Infections and Vaccines (13 papers), Pneumonia and Respiratory Infections (12 papers) and Virology and Viral Diseases (6 papers). Roger Maansson collaborates with scholars based in United States, United Kingdom and Belgium. Roger Maansson's co-authors include Alain Luxembourg, Xavier Castellsagué, Erin Moeller, Anna R. Giuliano, Joshua Chen, John L. Perez, Johannes Beeslaar, Ole Mogensen, Stephen E. Goldstone and Timo Vesikari and has published in prestigious journals such as New England Journal of Medicine, PEDIATRICS and The Lancet Infectious Diseases.

In The Last Decade

Roger Maansson

18 papers receiving 418 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Roger Maansson United States	9	386	129	109	61	55	20	425
Elena Rosanna Frati Italy	14	319 0.8×	80 0.6×	110 1.0×	36 0.6×	29 0.5×	28	379
Maria Garefalakis Australia	4	404 1.0×	78 0.6×	174 1.6×	38 0.6×	47 0.9×	4	450
Bernal Cortés Costa Rica	9	220 0.6×	57 0.4×	86 0.8×	55 0.9×	21 0.4×	15	309
Kavita Panwar United Kingdom	10	365 0.9×	52 0.4×	194 1.8×	40 0.7×	40 0.7×	20	418
Anna Barbara Moscicki United States	10	317 0.8×	84 0.7×	144 1.3×	63 1.0×	13 0.2×	12	425
Murdo Ferguson Belgium	10	286 0.7×	59 0.5×	35 0.3×	79 1.3×	32 0.6×	15	318
Tiina Petäjä Finland	7	509 1.3×	33 0.3×	190 1.7×	140 2.3×	57 1.0×	13	556
Brahim Qadadri United States	13	628 1.6×	154 1.2×	333 3.1×	36 0.6×	31 0.6×	22	697
Katherine Giacoletti United States	6	673 1.7×	44 0.3×	315 2.9×	152 2.5×	85 1.5×	8	739
Lan Lin Belgium	8	282 0.7×	26 0.2×	88 0.8×	83 1.4×	16 0.3×	9	318

Countries citing papers authored by Roger Maansson

Since Specialization

Citations

This map shows the geographic impact of Roger Maansson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger Maansson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger Maansson more than expected).

Fields of papers citing papers by Roger Maansson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roger Maansson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger Maansson. The network helps show where Roger Maansson may publish in the future.

Co-authorship network of co-authors of Roger Maansson

This figure shows the co-authorship network connecting the top 25 collaborators of Roger Maansson. A scholar is included among the top collaborators of Roger Maansson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roger Maansson. Roger Maansson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Martinón‐Torres, Federico, Mika Rämet, Ryan Newton, et al.. (2025). A Phase 3B, Open-Label Study to Evaluate the Immunogenicity and Safety of the Quadrivalent Meningococcal Nimenrix® Vaccine When Given to Healthy Infants at 3 and 12 Months of Age. Infectious Diseases and Therapy. 14(2). 463–481.

Peterson, James T., Jason D. Maguire, Roger Maansson, et al.. (2024). Randomized trial showing persistence of hSBA titers elicited by a pentavalent meningococcal MenABCWY vaccine for up to 4 years following a primary series and safety and immunogenicity of a booster dose. Vaccine. 43(Pt 1). 126469–126469.

Peterson, James T., Hanna Czajka, Jason D. Maguire, et al.. (2023). Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial. The Lancet Infectious Diseases. 23(12). 1370–1382. 8 indexed citations

Beeslaar, Johannes, Susan Mather, Judith Absalon, et al.. (2022). Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older. Vaccine. 40(12). 1872–1878. 2 indexed citations

Marshall, Helen, Timo Vesikari, Peter Richmond, et al.. (2022). Safety and immunogenicity of a primary series and booster dose of the meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) in healthy children aged 1–9 years: two phase 2 randomised, controlled, observer-blinded studies. The Lancet Infectious Diseases. 23(1). 103–116. 4 indexed citations

Østergaard, Lars, Timo Vesikari, Shelly Senders, et al.. (2021). Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months. Vaccine. 39(32). 4545–4554. 7 indexed citations

Czajka, Hanna, Jason D. Maguire, Roger Maansson, et al.. (2021). A phase 3 study to assess the immunogenicity, safety, and tolerability of MenB-FHbp administered as a 2-dose schedule in adolescents and young adults. Vaccine. 40(2). 351–358. 7 indexed citations

Beeslaar, Johannes, Judith Absalon, Annaliesa S. Anderson, et al.. (2020). MenB-FHbp Vaccine Protects Against Diverse Meningococcal Strains in Adolescents and Young Adults: Post Hoc Analysis of Two Phase 3 Studies. Infectious Diseases and Therapy. 9(3). 641–656. 4 indexed citations

Beeslaar, Johannes, Paula Peyrani, Judith Absalon, et al.. (2020). Sex, Age, and Race Effects on Immunogenicity of MenB-FHbp, A Bivalent Meningococcal B Vaccine: Pooled Evaluation of Clinical Trial Data. Infectious Diseases and Therapy. 9(3). 625–639. 3 indexed citations

10.

Peterson, James T., Hanna Czajka, Jason D. Maguire, et al.. (2020). 6. Pentavalent Meningococcal (MenABCWY) Vaccine is Safe and Well Tolerated With Immunogenicity Noninferior to Coadministered MenB-FHbp and MenACWY-CRM in a Phase 2 Study of Healthy Adolescents and Young Adults. Open Forum Infectious Diseases. 7(Supplement_1). S25–S26. 3 indexed citations

11.

Vesikari, Timo, Lars Østergaard, Johannes Beeslaar, et al.. (2019). Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents. Vaccine. 37(12). 1710–1719. 28 indexed citations

12.

Beeslaar, Johannes, Judith Absalon, Paul Balmer, et al.. (2018). Clinical data supporting a 2-dose schedule of MenB-FHbp, a bivalent meningococcal serogroup B vaccine, in adolescents and young adults. Vaccine. 36(28). 4004–4013. 6 indexed citations

13.

Maansson, Roger, David Radley, Qin Jiang, et al.. (2018). Modeling excess zeroes in an integrated analysis of vaccine safety. Human Vaccines & Immunotherapeutics. 14(6). 1530–1533. 1 indexed citations

14.

Østergaard, Lars, Timo Vesikari, Judith Absalon, et al.. (2017). A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults. New England Journal of Medicine. 377(24). 2349–2362. 51 indexed citations

15.

Castellsagué, Xavier, Anna R. Giuliano, Stephen E. Goldstone, et al.. (2015). Immunogenicity and safety of the 9-valent HPV vaccine in men. Vaccine. 33(48). 6892–6901. 93 indexed citations

16.

Luxembourg, Alain, Edson Duarte Moreira, Rudiwilai Samakoses, et al.. (2015). Phase III, randomized controlled trial in girls 9-15 years old to evaluate lot consistency of a novel nine-valent human papillomavirus L1 virus-like particle vaccine. Human Vaccines & Immunotherapeutics. 11(6). 1306–1312. 14 indexed citations

17.

Kosalaraksa, Pope, Jesper Mehlsen, Timo Vesikari, et al.. (2015). An Open-Label, Randomized Study of a 9-Valent Human Papillomavirus Vaccine Given Concomitantly with Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccines to Healthy Adolescents 11–15 Years of Age. The Pediatric Infectious Disease Journal. 34(6). 627–634. 27 indexed citations

18.

Luxembourg, Alain, Darron R. Brown, Céline Bouchard, et al.. (2015). Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine. Human Vaccines & Immunotherapeutics. 11(6). 1313–1322. 28 indexed citations

19.

Damme, Pierre Van, S. Block, Xavier Castellsagué, et al.. (2015). Immunogenicity and Safety of a 9-Valent HPV Vaccine. PEDIATRICS. 136(1). e28–e39. 93 indexed citations

20.

Schilling, Andrea, Eli Engel, Luis Huicho, et al.. (2015). Coadministration of a 9-Valent Human Papillomavirus Vaccine With Meningococcal and Tdap Vaccines. PEDIATRICS. 136(3). e563–e572. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact